Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback